Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

- Cerinic Interstitial lung disease in systemic sclerosis

Lung involvement frequently complicates systemic sclerosis (SSc), provoking loss of quality of life and a poor expectation of survival. For this reason an early diagnosis of lung involvement is warranted: high-resolution computed tomography (HRCT), pulmonary function tests (PFT), lung scintigraphy with DTPA and bronchoalveolar lavage (BAL) are mandatory to define and follow-up pulmonary interst...

Interstitial lung disease in systemic sclerosis

Systemic sclerosis (SSc) is a connective tissue disease characterised by autoimmune features, widespread vasculopathy and fibrosis of the skin and internal organs. The pattern of internal organ involvement and the natural history of the disease are highly variable. Although the etiology is unknown, most studies point to links between genetic predisposition and environmental factors. SSc has bee...

Is systemic sclerosis interstitial lung disease slowly progressive?

Genetic Susceptibility to Interstitial Lung Disease Associated with Systemic Sclerosis

Systemic sclerosis (SSc) is a connective tissue disease that is characterized by tissue fibrosis, microvasculopathy, and autoimmunity. Interstitial lung disease (ILD) is a common complication of SSc and is one of the frequent causes of mortality in SSc. Although the exact etiology of SSc remains unknown, clinical and experimental investigations have suggested that genetic and environmental fact...

The role of vasodilators in patients with progressive systemic sclerosis. Interstitial lung disease and pulmonary hypertension.

The use of systemic vasodilator drugs in reducing pulmonary artery pressures in patients with pulmonary hypertension is controversial. The effect of hydralazine in four patients with pulmonary hypertension resulting from interstitial lung disease (group 1) and nifedipine in four patients with pulmonary hypertension secondary to progressive systemic sclerosis (group 2) was investigated. Hydralaz...